Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.58 USD
Change Today +0.0287 / 5.22%
Volume 982.7K
DCTH On Other Exchanges
DCTH is not on other exchanges.
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Key Developments

Delcath Receives Orphan Drug Designation from FDA for Melphalan to Treat Cholangiocarcinoma

Delcath Systems, Inc. announced that the U.S. Food and Drug Administration(FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. The OOPD is tasked with evaluating the scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the liver. It is the second most common primary liver tumor and represents approximately 15% of new HCC cases diagnosed annually. Surgical resection, the standard of care, is not possible for an estimated 80% to 90% of patients diagnosed with ICC. The Company recently announced the expansion of its global Phase 2 clinical study in primary liver cancer (HCC) to include an ICC cohort, which is investigating the safety and efficacy of Melphalan/HDS treatment in patients with unresectable ICC confined to the liver. The study is being conducted at the same hospitals in Europe participating in the Company's Phase 2 HCC trial, and is expected to enroll 11 patients. The ICC cohort will evaluate tumor response (objective response rate) as measured by modified Response Evaluation Criteria in Solid Tumor (mRECIST), and will assess progression-free survival and safety. Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well as to assess patient-reported clinical outcomes, or quality-of-life.

Delcath Systems, Inc. Approves the Appointment of Grant Thornton, LLP as Independent Registered Public Accounting Firm for the Year Ending December 31, 2015

Delcath Systems, Inc. approved the appointment of Grant Thornton, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2015 at its AGM held on June 10, 2015.

Delcath Systems, Inc. - Shareholder/Analyst Call

Annual Meeting of Shareholders

Delcath Systems, Inc. Names Dr. Jennifer Simpson as its President and Chief Executive Officer

Delcath Systems, Inc. announced that Jennifer Simpson, Ph.D., M.S.N., C.R.N.P. has been named President and Chief Executive Officer by the company's Board of Directors, effective immediately. Dr. Simpson has served as Interim President and Chief Executive Officer of Delcath since September 2014 and as Interim Co-President and Co-Chief Executive Officer from September 2013 to September 2014. She joined Delcath in 2012 as Executive Vice President, Global Marketing. Prior to joining Delcath. Dr. Simpson was Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc. Dr. Simpson served as Vice President, Product Champion and from 2008 to 2009 as Associate Vice President, Product Champion for a late-stage asset at ImClone.

Delcath Systems, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Delcath Systems, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $444,000 compared to $310,000 a year ago. Operating loss was $3,708,000 compared to $5,059,000 a year ago. Net loss was $3,488,000 compared to $5,278,000 a year ago. Basic and diluted loss per share was $0.32 compared to $0.57 a year ago. Cash and cash equivalents as of March 31, 2015 were $18.5 million, compared with $20.5 million as of December 31, 2014. During the first quarter of 2015, net cash used in operating activities was $4.4 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $0.58 USD +0.0287

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.36 USD -0.04
CTI BioPharma Corp $1.87 USD -0.06
Curis Inc $3.17 USD 0.00
Exact Sciences Corp $24.51 USD -0.39
Sirtex Medical Ltd A$30.37 AUD -0.53
View Industry Companies

Industry Analysis


Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at